Dr. Winter Discusses the ZUMA-7 Trial in DLBCL

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial in diffuse large B-cell lymphoma (DLBCL; NCT03391466).

The ZUMA-7 study is evaluating the efficacy of the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) compared to standard of care therapy in patients with relapsed/refractory DLBCL. In this phase III randomized, open-label, multicenter study, patients will be randomized to receive axi-cel or standard of care second-line therapy following treatment with first-line rituximab (Rituxan) and anthracycline-based chemotherapy.

Winter says that immunotherapy may be the best strategy for patients with relapsed/refractory DLBCL. This is very exciting for these patients, Winter explains, because there are not many therapeutic choices for this population.